Problem

ChronicleBio addresses the biomedical blind spot around complex chronic and neuroimmune conditions such as POTS, ME/CFS, and Long COVID. These illnesses affect nearly 300 million people worldwide yet remain woefully understudied, leaving patients without meaningful treatments. The central pain is a lack of connected, research-grade clinical, molecular, biospecimen, and patient-reported data needed to understand disease mechanisms, diagnose patients, and develop therapies.

For biopharma and clinical researchers, this data gap makes historically overlooked and hard-to-crack therapeutic areas difficult to interrogate with scientific rigor. ChronicleBio’s main use case is to turn human health data and biosamples into disease signatures, biomarkers, biologically defined patient subgroups, trial-ready cohorts, and therapeutic opportunities.

Product / Service

ChronicleBio is building an end-to-end, AI-driven platform that spans biospecimen collection, multi-omic data integration, biological subtype discovery, and drug-target prioritization. Its proprietary data engine combines multi-omic, clinical, real-world, and patient-reported evidence into an AI-ready ecosystem intended to connect patient experience with clinical solutions.

The company delivers this through a global biobank, partnerships with clinics, research consortia, and biotech sponsors, and a decentralized clinical-trial network. Patients can contribute data and samples through research collaborations, while biotechnology companies and researchers gain integrated datasets for biomarker discovery, patient stratification, precision therapeutic development, and faster access to relevant patient populations.

Market

ChronicleBio sits at the intersection of techbio, AI-enabled drug discovery, precision medicine, real-world evidence, biobanking, and decentralized clinical-trial infrastructure. Its target customers are biotechnology companies, clinics, research consortia, and sponsors seeking to unlock difficult therapeutic areas, particularly neuroimmune and complex chronic diseases. The available company and industry materials do not name direct competitors; its competitive set is therefore best understood as adjacent data-driven drug-discovery and clinical-research platforms rather than a clearly disclosed list of rivals.

ChronicleBio launched publicly in August 2025 and reported that its platform was already being used by multiple high-integrity clinics in the United States and India, with thousands of patients contributing data and biosamples. It also launched a research partnership involving Solve M.E., the Brain Inflammation Collaborative, the Complex Disorders Alliance, and CareEvolution. A 2026 company profile reports $10.3 million raised; because that profile leaves current revenue blank, ChronicleBio is best characterized as an early-stage, pre-revenue or not-yet-publicly-revenue-disclosed platform company rather than a scaled commercial biotech.